Back to top
more

IDEXX Laboratories (IDXX)

(Delayed Data from NSDQ)

$423.65 USD

423.65
553,842

-6.17 (-1.44%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $423.84 +0.19 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (69 out of 250)

Industry: Medical - Instruments

Zacks News

Cooper to Benefit From Specialty Lenses Prospects Amid Woes

The Cooper Companies' (COO) strong sales growth will continue to be aided by a leading position in the market of specialty lenses.

    Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead

    The share price performance of Abbott Laboratories (ABT) has been disappointing over the last three years. Of the prime issues plaguing Abbott, foreign exchange is a major one.

      Align Technology at 52-Week High: What's Driving the Stock?

      Align Technology's (ALGN) efforts to expand worldwide instil confidence in investors. The market is upbeat about the non-exclusive distribution agreement with Patterson Dental.

        Buy These 5 Large Caps on Extraordinary ROI Potential

        Amid heightening tensions in the Korean Peninsula and hurricanes back home, let's take the safer route and invest for the long haul, using ROI as a barometer.

          Boston Scientific Grows on Innovation, Buyouts Amid Woes

          While unfavorable foreign exchange continues to raise concerns, Boston Scientific (BSX) stands steadily on growth track with Symetis acquisition and FDA-approved products.

            HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates

            HealthEquity (HQY) delivered favorable results in the second quarter of fiscal 2018 on the back of revenue and margin expansion.

              Allscripts' (MDRX) dbMotion Platform Selected by SWSPHN

              The latest development is a significant addition to Allscripts' (MDRX) dbMotion Solution platform customer base. The company is poised to benefit from opportunities in the Asia-Pacific market.

                Henry Schein Joins IMF & LUGFA on Prostate Cancer Awareness

                Henry Schein (HSIC) joins forces with IMF and LUGPA to generate awareness among physicians and people about the importance of early detection of prostate cancer.

                  Quest Diagnostics (DGX) Banks on Buyouts, Competition Rife

                  Quest Diagnostics (DGX) witnesses significant growth through infectious disease testing, prescription drug monitoring and wellness business.

                    Medtronic (MDT) & Mazor Robotics Tie-Up Reaches Next Level

                    With an investment of $40 million as a third installment in Mazor Robotics, Medtronic (MDT) will become the exclusive worldwide distributor of the Mazor X system.

                      Hologic (HOLX) Launches Brevera, Progresses in Breast Health

                      Hologic's (HOLX) Brevera real-time breast biopsy and verification system holds great potential to enhance workflow and patient experience.

                        4 Large-Cap Medical Device Stocks to Buy Amid Political Woes

                        Investors facing political doldrums can safely place their bets on the Medical Device space on four large-cap medical device stocks that are poised for impressive returns over the next five years.

                          Mazor Robotics Hits 52-Week High Through Medtronic Alliance

                          Mazor Robotics (MZOR) touched a new 52-week high on the back of favorable amendment of its strategic partnership with Medtronic.

                            GNC Holdings Gains on New GNC Strength Amid Soft Revenues

                            GNC Holdings (GNC) continues to bank on new GNC plan and global revenues despite lacklustre revenue figures in second quarter of 2017.

                              3 MedTech Stocks Set to Rally in the Second Half

                              The wide gamut of Medical Device presents interesting choice for investors to profit from rally in the second half of 2017.

                                Haemonetics Grows on Strong Plasma, Blood Center Sluggish

                                Haemonetics' (HAE) encouraging growth in both Plasma and Haemonetics Management franchises keeps the market upbeat. However, slow revenue growth at the Blood Center franchise raises concern.

                                  Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod

                                  Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest Japanese national reimbursement grant.

                                    The Cooper Companies (COO) Beats Earnings Estimates in Q3

                                    The Cooper Companies (COO) provided strong guidance for fiscal 2017. However, the soft outlook for CooperSurgical indicates looming concerns.

                                      Amedisys to Buy Intercity Home Care, Boosts Personal Care Arm

                                      Amedisys (AMED) to strengthen its position in Personal Care business in Massachusetts with this recently signed acquisition deal.

                                        Abbott's AMPLATZER Pivotal Study to Strengthen Vascular Arm

                                        Abbott (ABT) is consistently trying to expand its vascular business. It has initiated the clinical study of AMPLATZER device to correct common congenital heart defect in newborns.

                                          BioScrip's Infusion Business Strong, Dull 2017 View a Drag (Revised)

                                          BioScrip's (BIOS) progressive CORE plan should enhance its financial position. However, the company's 2017 outlook loses steam based on an anticipated adverse impact of Cures Act legislation.

                                            Phibro Animal (PAHC) Beats Q4 Earnings & Sales Estimates

                                            Phibro Animal (PAHC) reported solid fourth-quarter fiscal 2017 revenues on the back of sales growth in the Animal Health, Mineral Nutrition and Performance Products segments.

                                              VWR Awaits Merger Closure, Stock Upside Potential Limited

                                              VWR Corporation's (VWR) $6.4 billion acquisition by Avantor should create a major consumables-focused solutions and services provider to lucrative life sciences and advanced technologies industries.

                                                Cooper (COO) Poised to Grow on Specialty Lenses Prospects

                                                Cooper's (COO) strong sales growth will continue to be aided by its leading position in the markets of specialty lenses.

                                                  Thermo Fisher Acquires Patheon, Boosts Laboratory Products

                                                  Thermo Fisher's (TMO) acquisition of Patheon significantly strengthens its Pharmaceutical and Biotech business by adding complementary services.